Primary mediastinal large B-cell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: What is the oncologist to do?

Current Hematologic Malignancy Reports

Volumn 6, Issue 3, 2011, Pages 157-163

  Grant, Cliona ^a   Dunleavy, Kieron ^a   Eberle, Franziska C ^b   Pittaluga, Stefania ^a   Wilson, Wyndham H ^a   Jaffe, Elaine S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Chemotherapy; Diffuse large B cell lymphoma; DLBCL; Epigenetics; Gene expression profiling; Gray zone lymphoma; Grey zone lymphoma; Hodgkin lymphoma; Hodgkin's disease; Immunophenotyping; Mediastinal lymphomas; Microenvironment; Primary mediastinal large B cell lymphoma; Radiation therapy; Thymic lymphoma

Indexed keywords

BLEOMYCIN; CD103 ANTIGEN; CD15 ANTIGEN; CD20 ANTIGEN; CD23 ANTIGEN; CD30 ANTIGEN; CD45 ANTIGEN; CD79A ANTIGEN; CHLORMETHINE; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; IMMUNOGLOBULIN; METHOTREXATE; OCTAMER TRANSCRIPTION FACTOR 2; PREDNISONE; PROCARBAZINE; PROTEIN BCL 6; RITUXIMAB; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR BOB1; TRANSCRIPTION FACTOR PAX5; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER MORPHOLOGY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHROMOSOME 2P; CHROMOSOME 9P; CHROMOSOME ANALYSIS; CLASSICAL HODGKIN LYMPHOMA; EVENT FREE SURVIVAL; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HUMAN; IMMUNOGLOBULIN PRODUCTION; IMMUNOPHENOTYPING; INFLAMMATORY INFILTRATE; LARGE CELL LYMPHOMA; MEDIASTINAL GRAY ZONE LYMPHOMA; MEDIASTINUM CANCER; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NODULAR SCLEROSIS HODGKIN LYMPHOMA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; TUMOR MICROENVIRONMENT;

CLINICAL TRIALS AS TOPIC; HODGKIN DISEASE; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, LARGE B-CELL, DIFFUSE; MEDIASTINAL NEOPLASMS;

EID: 80055052816     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-011-0090-1     Document Type: Article

References (49)

1. Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. Feb 7 2011 (Epub ahead of print).
2. Rudiger T, Jaffe ES, Delsol G, et al. Workshop report on Hodgkin's disease and related diseases ('grey zone' lymphoma). Ann Oncol. 1998;9 Suppl 5:S31-8. (Pubitemid 29049115)
3. Jaffe ES, Zarate-Osorno A, Medeiros LJ. The interrelationship of Hodgkin's disease and non-Hodgkin's lymphomas-lessons learned from composite and sequential malignancies. Semin Diagn Pathol. 1992;9:297-303.
4. Kuppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009;9:15-27.
5. Kanzler H, Kuppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med. 1996;184:1495-505. (Pubitemid 26354704)
6. Stein H, Marafioti T, Foss HD, et al. Down-regulation of BOB.1/ OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood. 2001;97:496-501. (Pubitemid 32060336)
7. Andrieu JM, Roithmann S, Tourani JM, et al. Hodgkin's disease during HIV1 infection: the French registry experience. French Registry of HIV-associated Tumors. Ann Oncol. 1993;4:635-41. (Pubitemid 23291808)
8. Levine AM. Hodgkin's disease in the setting of human immunodeficiency virus infection. J Natl Cancer Inst Monogr 1998:37-42.
9. Bellas C, Santon A, Manzanal A, et al. Pathological, immunological, and molecular features of Hodgkin's disease associated with HIV infection. Comparison with ordinary Hodgkin's disease. Am J Surg Pathol. 1996;20:1520-4. (Pubitemid 26411721)
10. Kamel OW, Weiss LM, van de Rijn M, Colby TV, Kingma DW, Jaffe ES. Hodgkin's disease and lymphoproliferations resembling Hodgkin's disease in patients receiving long-term low-dose methotrexate therapy. Am J Surg Pathol. 1996;20:1279-87. (Pubitemid 26336854)
11. Kumar S, Fend F, Quintanilla-Martinez L, et al. Epstein-Barr virus-positive primary gastrointestinal Hodgkin's disease: association with inflammatory bowel disease and immunosuppression. Am J Surg Pathol. 2000;24:66-73. (Pubitemid 30033398)
12. Traverse-Glehen A, Pittaluga S, Gaulard P, et al. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol. 2005;29:1411-21. (Pubitemid 41513290)
13. Schmid C, Pan L, Diss T, Isaacson PG. Expression of B-cell antigens by Hodgkin's and Reed-Sternberg cells. Am J Pathol. 1991;139:701-7.
14. Zukerberg LR, Collins AB, Ferry JA, Harris NL. Coexpression of CD15 and CD20 by Reed-Sternberg cells in Hodgkin's disease. Am J Pathol. 1991;139:475-83.
15. Loddenkemper C, Anagnostopoulos I, Hummel M, et al. Differential Emu enhancer activity and expression of BOB.1/ OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas. J Pathol. 2004;202:60-9. (Pubitemid 38072846)
16. Foss HD, Reusch R, Demel G, et al. Frequent expression of the Bcell- specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin. Blood. 1999;94:3108-13. (Pubitemid 29512717)
17. Lichtenstein AK, Levine A, Taylor CR, et al. Primary mediastinal lymphoma in adults. Am J Med. 1980;68:509-14. (Pubitemid 10141815)
18. Higgins JP, Warnke RA. CD30 expression is common in mediastinal large B-cell lymphoma. Am J Clin Pathol. 1999;112:241-7. (Pubitemid 30212541)
19. Moller P, Lammler B, Eberlein-Gonska M, et al. Primary mediastinal clear cell lymphoma of B-cell type. Virchows Arch A Pathol Anat Histopathol. 1986;409:79-92. (Pubitemid 16071513)
20. Paulli M, Strater J, Gianelli U, et al. Mediastinal B-cell lymphoma: a study of its histomorphologic spectrum based on 109 cases. Hum Pathol. 1999;30:178-87. (Pubitemid 29086949)
21. Pileri SA, Zinzani PL, Gaidano G, et al. Pathobiology of primary mediastinal B-cell lymphoma. Leuk Lymphoma. 2003;44 Suppl 3: S21-6. (Pubitemid 38196059)
22. Moller P, Moldenhauer G, Momburg F, et al. Mediastinal lymphoma of clear cell type is a tumor corresponding to terminal steps of B cell differentiation. Blood. 1987;69:1087-95. (Pubitemid 17080929)
23. Pileri SA, Gaidano G, Zinzani PL, et al. Primary mediastinal Bcell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. Am J Pathol. 2003;162:243-53. (Pubitemid 36042006)
24. Calaminici M, Piper K, Lee AM, Norton AJ. CD23 expression in mediastinal large B-cell lymphomas. Histopathology. 2004;45:619-24. (Pubitemid 40029822)
25. Salama ME. Rajan Mariappan M, Inamdar K, Tripp SR, Perkins SL. The value of CD23 expression as an additional marker in distinguishing mediastinal (thymic) large B-cell lymphoma from Hodgkin lymphoma. Int J Surg Pathol. 2010;18:121-8.
26. Garcia JF, Mollejo M, Fraga M, et al. Large B-cell lymphoma with Hodgkin's features. Histopathology. 2005;47:101-10. (Pubitemid 40978819)
27. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198:851-62. (Pubitemid 37152922)
28. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102:3871-9. (Pubitemid 37486965)
29. Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116:3268-77.
30. Oschlies I, Burkhardt B, Salaverria I, et al. Clinical, pathological and genetic features of primary mediastinal large Bcell lymphomas and mediastinal gray zone lymphomas in children. Haematologica 2011;96:262-8. This is a recent clinical study of mediastinal lymphomas in children, and is a useful comparison with the adult experience.
31. Hertel CB, Zhou XG, Hamilton-Dutoit SJ, Junker S. Loss of B cell identity correlates with loss of B cell-specific transcription factors in Hodgkin/Reed-Sternberg cells of classical Hodgkin lymphoma. Oncogene. 2002;21:4908-20.
32. Ehlers A, Oker E, Bentink S, Lenze D, Stein H, Hummel M. Histone acetylation and DNA demethylation of B cells result in a Hodgkin-like phenotype. Leukemia 2008;22:835-41. (Pubitemid 351552633)
33. Eberle FC, Rodriguez-Canales J, Wei L, et al. Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma. Haematologica 2011;96:558-66.
34. Cazals-Hatem D, Andre M, Mounier N, et al. Pathologic and clinical features of 77 Hodgkin's lymphoma patients treated in a lymphoma protocol (LNH87): a GELA study. Am J Surg Pathol. 2001;25:297-306. (Pubitemid 32174198)
35. Longo DL, Glatstein E, Duffey PL, et al. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease. J Clin Oncol. 1997;15:3338-46. (Pubitemid 27485852)
36. Longo DL, Russo A, Duffey PL, et al. Treatment of advancedstage massive mediastinal Hodgkin's disease: the case for combined modality treatment. J Clin Oncol. 1991;9:227-35.
37. Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004;104:3483-9. (Pubitemid 39564416)
38. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23:4634-42. (Pubitemid 46237440)
39. Castellino SM, Geiger AM, Mertens AC, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood. 2011;117:1806-16.
40. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increaseddose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003;348:2386-95. (Pubitemid 36682817)
41. Zinzani PL, Martelli M, Magagnoli M, et al. Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients. Blood. 1999;94:3289-93. (Pubitemid 29536121)
42. Todeschini G, Secchi S, Morra E, et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer. 2004;90:372-6. (Pubitemid 38250631)
43. Rieger M, Osterborg A, Pettengell R, et al. Primary mediastinal Bcell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol. 2011;22:664-70.
44. Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99:2685-93. (Pubitemid 34525353)
45. Wilson WH, Gutierrez M, O'Connor P, et al. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R. Semin Oncol. 2002;29:41-7. (Pubitemid 34171794)
46. Dunleavy K, Pittaluga S, Tay K, et al. Comparative clinical and biological features of primary mediastinal B-cell lymphoma (PMBL) and mediastinal grey zone lymphoma (MGZL). ASH Annual Meeting Abstracts. 2009;114:106.
47. Dunleavy K, Pittaluga S, Shovlin M. Untreated Primary Mediastinal B-cell (PMBL) and Mediastinal Grey Zone (MGZL) Lymphomas: Comparison of biological features and clinical outcome following DA-EPOCH-R without radiation [abstract]. Submitted, 11th International Conference on Malignant Lymphoma, Lugano; 2011.
48. Steidl C, Lee T, Shah SP, Farinha P, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010;362:875-85.
49. Steidl C, Shah SP, Woolcock BW, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011;471(7338):377-81.